论药品监管信息化项目的精细化管理

Fine Management of Drug Regulatory Informatization Projects

摘要: 本研究旨在探讨药品监管信息化项目的精细化管理，以提升药品监督管理的现代化水平和实现健康中国建设目标。随着医药科技的进步和市场的快速发展，药品监管任务变得日益繁重和复杂，信息化技术的应用成为提高监管效能的关键。研究通过建立电子监管平台，实现了数据资源共享、流程协同作业和决策支持系统化，有效提升了药品审评审批、生产流通、使用监督等工作的科学化和规范化水平。本研究设计并实施了针对药品监管领域的信息化项目精细化管理工具，通过流程、数据、质量、风险、成本和绩效等方面的管理，提高了管理效率、标准化和自动化药监信息化项目的管理流程，降低了人力资源消耗，并实时发现潜在风险和问题。此外，研究还推进了药监部门治理能力的现代化，提升了公共服务的整体水平。研究结果表明，精细化管理在药品监管信息化项目中的应用显著提升了监管效能、保障了药品质量与安全、降低了风险成本，并推动了药品监管体系的现代化。

Abstract: This study aims to explore the refined management of the drug regulatory informationization project, in order to enhance the modernization level of drug supervision and achieve the goals of building a healthy China. With the advancement of medical technology and rapid market development, drug regulatory tasks have become increasingly heavy and complex, and the application of information technology has become the key to improving regulatory efficiency. By establishing an electronic supervision platform, this study achieved data resource sharing, process collaboration, and systematic decision support, effectively enhancing the scientific and standardized level of drug evaluation, approval, production, circulation, and usage supervision. This study designed and implemented refined management tools for informationization projects in the drug regulatory field. Through management aspects including processes, data, quality, risk, cost, and performance, it increased management efficiency, standardized and automated the management process of drug regulatory informationization projects, reduced human resource consumption, and promptly detected potential risks and issues. In addition, the study also advanced the modernization of the governance capability of drug regulatory departments, enhancing the overall level of public services. The results of the study indicate that the application of refined management in the drug regulatory informationization project significantly improved regulatory efficiency, ensured drug quality and safety, reduced risk costs, and promoted the modernization of the drug regulatory system.